## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract
- **Shared manuscript claim summary** The authors propose DMDGRN, a data augmentation-based multilayer directed graph convolutional network for gene regulatory network (GRN) inference. The method uses a phase matrix to construct a directed Laplacian operator, incorporates data augmentation to address network sparsity, and employs residual connections in a multilayer architecture to capture higher-order neighborhood information. The authors report improved inference accuracy on benchmark datasets and successful identification of therapeutic candidates in a breast cancer application.
- **Visible evidence base** Abstract text only; no figures, tables, methods details, or quantitative results are provided
- **Missing materials affecting confidence** Full manuscript, benchmark dataset descriptions, baseline comparisons, quantitative performance metrics, implementation details, hyperparameter settings, and the breast cancer case study results

## Reviewer
- **Overall assessment** The abstract presents a plausible methodological contribution to GRN inference, combining directed graph convolution with data augmentation and multilayer residual architecture. However, the evidence provided is insufficient to evaluate the technical soundness, the validity of the performance claims, or the significance of the biological application. The core claims of improved accuracy and therapeutic candidate identification are stated without quantitative support. The manuscript may have merit, but the case is not established from the supplied material.
- **Who would be interested in the results, and why** Computational biologists and bioinformaticians working on gene regulatory network inference, graph neural network applications in biology, and network-based approaches to disease mechanism discovery. Researchers developing methods for directed graph representation learning may also find the methodological aspects relevant.
- **Major strengths** The abstract identifies a clear gap in existing GRN inference methods, namely the neglect of directionality, sparsity, and higher-order interactions. The proposed combination of a phase matrix for directed Laplacian construction, data augmentation for sparsity, and residual connections for higher-order information is a coherent and potentially novel methodological strategy. The inclusion of a breast cancer application suggests translational relevance.
- **Major Concerns**  
  - **Concern ID** R1-M1  
  - **Severity** Major  
  - **Blocking** Yes  
  - **Axis** Technical soundness  
  - **Claim pointer** "DMDGRN employs phase matrix to construct the Laplacian operator, which can track message propagation pathways"  
  - **Evidence pointer** Methods section, location not provided  
  - **Concern** The abstract does not describe how the phase matrix is defined, how it encodes directionality in the Laplacian, or whether the resulting operator preserves desirable spectral properties for graph convolution. No mathematical formulation or algorithmic details are given.  
  - **Why it matters** The directed Laplacian construction is the central methodological novelty. Without a clear and verifiable formulation, the technical validity of the approach cannot be assessed, and the claim of capturing directionality remains unsupported.  
  - **Resolution test** Provide the explicit mathematical definition of the phase matrix and the directed Laplacian, including how directionality is encoded and how message passing is affected. Include a derivation or reference that establishes the correctness and stability of the operator.

  - **Concern ID** R1-M2  
  - **Severity** Major  
  - **Blocking** Yes  
  - **Axis** Evidence quality  
  - **Claim pointer** "Comprehensive evaluations on benchmark datasets demonstrate that DMDGRN significantly improves GRN inference accuracy"  
  - **Evidence pointer** Results section, location not provided  
  - **Concern** No quantitative results are reported. The abstract does not specify which benchmark datasets were used, which baseline methods were compared, what performance metrics were employed, or the magnitude of improvement. The word "significantly" is used without statistical or effect-size support.  
  - **Why it matters** The central claim of the paper is improved inference accuracy. Without numerical evidence, the claim is unverifiable and the practical value of the method cannot be determined.  
  - **Resolution test** Report performance metrics (e.g., AUROC, AUPRC) on standard benchmarks such as BEELINE, compare against established baselines, and provide statistical significance tests or confidence intervals.

  - **Concern ID** R1-M3  
  - **Severity** Major  
  - **Blocking** Yes  
  - **Axis** Evidence quality  
  - **Claim pointer** "The application on breast cancer shows that our framework successfully identifies relevant therapeutic candidates for human breast cancer"  
  - **Evidence pointer** Results section, location not provided  
  - **Concern** The abstract provides no details on the breast cancer dataset, the nature of the identified candidates, how relevance was determined, or whether any validation (e.g., literature support, experimental confirmation) was performed.  
  - **Why it matters** The translational claim is a key selling point. Without evidence of biological validity or clinical relevance, the claim is anecdotal and does not support the stated potential for therapeutic target identification.  
  - **Resolution test** Describe the breast cancer dataset, list the identified candidates, and provide evidence of relevance such as literature corroboration, differential expression analysis, or functional enrichment.

  - **Concern ID** R1-M4  
  - **Severity** Major  
  - **Blocking** No  
  - **Axis** Reproducibility  
  - **Claim pointer** "DMDGRN incorporates data augmentation techniques to overcome the network sparsity"  
  - **Evidence pointer** Methods section, location not provided  
  - **Concern** The abstract does not specify which data augmentation techniques are used, how they are applied to graph-structured data, or how they interact with the directed convolution operation.  
  - **Why it matters** Data augmentation in graph neural networks is non-trivial and can introduce bias or alter the graph structure in unintended ways. Without details, the approach is not reproducible and its effect on performance cannot be isolated.  
  - **Resolution test** Specify the augmentation strategies (e.g., edge dropout, node feature perturbation), the rationale for their selection, and ablation studies showing their contribution to performance.

- **Minor Comments**  
  - **Concern ID** R1-m1  
  - **Severity** Minor  
  - **Axis** Clarity  
  - **Affected element** Abstract wording  
  - **Evidence pointer** Abstract, location not provided  
  - **Issue** The phrase "the inherent characteristics of GRNs usually have been ignored" is vague. It is unclear whether the authors mean ignored by all existing methods or only by graph neural network-based methods.  
  - **Required correction** Clarify the scope of the critique by specifying which existing methods fail to address directionality, sparsity, and higher-order interactions.

  - **Concern ID** R1-m2  
  - **Severity** Minor  
  - **Axis** Completeness  
  - **Affected element** Conclusion  
  - **Evidence pointer** Abstract, location not provided  
  - **Issue** The conclusion states that the strategies are "effective" but does not contextualize the findings relative to prior work or discuss limitations.  
  - **Required correction** Add a brief statement on limitations and how the method compares conceptually to existing directed GRN inference approaches.

  - **Concern ID** R1-m3  
  - **Severity** Minor  
  - **Axis** Terminology  
  - **Affected element** Method description  
  - **Evidence pointer** Abstract, location not provided  
  - **Issue** The term "multilayer directed graph convolutional network" is used, but the abstract does not clarify whether "multilayer" refers to multiple graph convolution layers, multiple network modules, or both.  
  - **Required correction** Define "multilayer" explicitly in the methods description.

- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3. The directed Laplacian formulation must be provided and validated, quantitative benchmark results must be reported, and the breast cancer application must be substantiated with concrete evidence.

- **Assessment against Nature-style criteria**  
  - **Originality** The combination of a phase matrix for directed Laplacian construction with data augmentation and residual connections appears novel, but the abstract does not provide enough detail to distinguish it clearly from existing directed GNN methods. Originality is plausible but not fully established.  
  - **Scientific importance** GRN inference is a central problem in systems biology, and improved methods have broad relevance. However, the importance of the specific contribution cannot be assessed without evidence of substantial performance gains over existing methods.  
  - **Interdisciplinary readership** The topic bridges computer science and biology, and the breast cancer application could attract translational researchers. The abstract is written in a way that is accessible to both communities, though technical details are lacking.  
  - **Technical soundness** Not assessable from the abstract. The core methodological claims are unverified, and the absence of mathematical or algorithmic details prevents evaluation.  
  - **Readability for nonspecialists** The abstract is generally clear and avoids excessive jargon, but terms such as "phase matrix" and "directed Laplacian operator" are introduced without explanation, which may hinder nonspecialist comprehension.

- **Recommendation posture** Currently not established from the provided evidence. The methodological idea is promising, but the abstract alone does not provide sufficient technical detail or quantitative support to assess the validity of the claims. A full manuscript with detailed methods, benchmark results, and biological validation would be required to evaluate the contribution properly.

## Risk / unsupported claims
- The claim of "significantly improves GRN inference accuracy" is unsupported due to the absence of quantitative results.
- The claim of "successfully identifies relevant therapeutic candidates" is unsupported due to the absence of dataset details, candidate lists, or validation evidence.
- The claim that the phase matrix "can track message propagation pathways" is unverifiable without the mathematical formulation.
- The claim that data augmentation "overcome[s] the network sparsity" is unverifiable without specification of the augmentation techniques and their effects.
- The overall conclusion that the strategies are "effective" is not supported by the evidence presented in the abstract.